Elvia Cowan - 09 Mar 2026 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
SVP, Finance & CAO
Signature
Elvia Cowan, by /s/ Peter N. Efremenko, Attorney-In-Fact
Issuer symbol
PCVX
Transactions as of
09 Mar 2026
Net transactions value
-$146,482
Form type
4
Filing time
11 Mar 2026, 17:23:56 UTC
Previous filing
02 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cowan Elvia SVP, Finance & CAO C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS Elvia Cowan, by /s/ Peter N. Efremenko, Attorney-In-Fact 11 Mar 2026 0001960048

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Tax liability -495 -1.6% $59.32* 30,867 09 Mar 2026 Direct F1
transaction PCVX Common Stock Options Exercise +2,500 +8.1% $25.92* 33,367 11 Mar 2026 Direct
transaction PCVX Common Stock Sale $146,482 -2,500 -7.5% $58.59 30,867 11 Mar 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise -2,500 -2.5% $0.000000* 96,068 11 Mar 2026 Common Stock 2,500 $25.92 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated January 29, 2026 were sold by the Reporting Person.
F2 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025.
F3 1/4 of the shares subject to the option vested on July 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.